|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016694,
umls-concept:C0030705,
umls-concept:C0138741,
umls-concept:C0205251,
umls-concept:C0231174,
umls-concept:C0242792,
umls-concept:C0376358,
umls-concept:C0392752,
umls-concept:C1366489,
umls-concept:C1417779,
umls-concept:C1708760
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-8-29
|
|
pubmed:abstractText |
To determine whether the post-external beam radiotherapy (RT) prostate-specific antigen nadir (nPSA) improves our ability to predict freedom from PSA failure, progression-free survival (PFS), and overall survival. Controversy regarding the importance of nPSA after external beam RT as a prognostic indicator for patients with localized prostate cancer has continued.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-9995
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
492-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12946753-Adenocarcinoma,
pubmed-meshheading:12946753-Age Factors,
pubmed-meshheading:12946753-Aged,
pubmed-meshheading:12946753-Aged, 80 and over,
pubmed-meshheading:12946753-Disease-Free Survival,
pubmed-meshheading:12946753-Follow-Up Studies,
pubmed-meshheading:12946753-Humans,
pubmed-meshheading:12946753-Male,
pubmed-meshheading:12946753-Middle Aged,
pubmed-meshheading:12946753-Multivariate Analysis,
pubmed-meshheading:12946753-Neoplasm Staging,
pubmed-meshheading:12946753-Prostate-Specific Antigen,
pubmed-meshheading:12946753-Prostatic Neoplasms,
pubmed-meshheading:12946753-Risk Assessment,
pubmed-meshheading:12946753-Survival Rate,
pubmed-meshheading:12946753-Treatment Failure,
pubmed-meshheading:12946753-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143-1708, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
